🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06597630
Recruiting Observational

Pathological Type,Gene Mutation and Clinical Characteristics of Unilateral Primary Aldosteronism

NCT06597630 · tracked via the Priya Life Science China tracker
Sponsor
Qifu Li
Phase
Observational
Started
2023-12-01
Last updated
2024-09-19

Condition(s) studied

Primary Aldosteronism

Investigational drug(s) / intervention(s)

Tissue specimens were stained by histopathology of hematoxylin-eosin

Tissue specimens were stained by histopathology of hematoxylin-eosin: Whole slide images were created by scanning the complete histologic slide to produce high-resolution digital files of the histopathology of hematoxylin-eosin and CYP11B2 immunostained sections.Tissue sections of all blocks from each resected adrenal were evaluated by hematoxylin and eosin and CYP11B2 immunostaining and adrenal specimens were categorized as classical or nonclassical histopathologic findings of unilateral PA according to the HISTALDO consensus; Genotyping was performed using CYP11B2 (aldosterone synthase)-guided sequencing

Study summary

1. Aim to investigate the pathological feature of UPA in Asians
2. To clarify the relationship between pathology, clinical phenotype, genetic mutation and surgical outcome of UPA in Asians.
3. To explore a new pathological type of unilateral primary aldosterone

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. No gender limitation; 2. Age 18-80 years old; 3. The patient was diagnosed with UPA and underwent total adrenal resection. Exclusion Criteria: 1. Bilateral disease 2. Partial of no biochemical response in follow-up 3. partial adrenalectomy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Qifu Li, PhD Chongqing Chongqing Municipality Recruiting

More Qifu Li trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06597630 on ClinicalTrials.gov ↗ ← All trials in China